Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

April 18, 2023

Study Completion Date

June 1, 2023

Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)Type 2 Diabetes (T2DM)
Interventions
DRUG

Lanifibranor

The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day

OTHER

Placebo

Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.

Trial Locations (1)

32610

University of Florida, Gainesville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Inventiva Pharma

INDUSTRY

lead

University of Florida

OTHER

NCT03459079 - Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter